Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed operable primary muscle invasive bladder cancer~  * T2-T4a, NX or N0, M0 (stage II or III)~* Must have an adequate functioning bladder~* Must have undergone a prior transurethral resection of the bladder tumor within the past 8 weeks~* No evidence of tumor-related hydronephrosis~* No evidence of distant metastases or histologically or cytologically confirmed lymph node metastases~* Patients with involvement of the prostatic urethra with transitional cell cancer that was visibly completely resected are allowed~  * No evidence of stromal invasion of the prostate~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Hemoglobin at least 10 g/dL~* White blood cell (WBC) count at least 4,000/mm\^3~* Absolute neutrophil count at least 1,800/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Serum bilirubin no greater than 2.0 mg/dL~Renal~* Serum creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min NOTE: If the creatinine clearance is greater than 60 mL/min, creatinine of no greater than 1.8 mg/dL is allowed at the discretion of the study chair~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except nonmelanoma skin cancer, stage T1a prostate cancer, or carcinoma in situ of the cervix~* Must be able to tolerate systemic chemotherapy with pelvic radiotherapy and radical cystectomy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior systemic chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic radiotherapy~Surgery~* See Disease Characteristics~Other~* No concurrent drugs that have potential nephrotoxicity or ototoxicity (e.g., aminoglycosides)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pelvic RT + paclitaxel + cisplatin (Type: EXPERIMENTAL): Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
- Pelvic RT + fluorouracil + cisplatin (Type: EXPERIMENTAL): Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete